These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 4937755)

  • 21. [Animal experiment methods for the testing of fibrinolytic and antifibrinolytic agents].
    Klöcking HP; Markwardt F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1969; 92(1):84-9. PubMed ID: 4189378
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparative studies of the effect of fibrinolytic inhibitors (synthetic and naturally occurring substances) on coagulation and fibrinolytic systems in vitro and in vivo, and their clinical applications.
    Matsuoka M; Sakuragawa N; Yoneyama Y
    Acta Med Biol (Niigata); 1969 Mar; 16(3):105-20. PubMed ID: 4239124
    [No Abstract]   [Full Text] [Related]  

  • 23. [Influence of antiplasmin on fibrinolysis and fibrinogenolysis].
    Bratus' GM; Byshevskiĭ ASh
    Ukr Biokhim Zh; 1971; 43(2):178-82. PubMed ID: 4254692
    [No Abstract]   [Full Text] [Related]  

  • 24. Modifications of bleeding time and intensity of prothrombin consumption and of fibrinolysis in rats after administration of platelet extracts alone and with antifibrinolytic agents.
    De Nicola P; Lüscher EF; Soardi F; Gibelli A; Cipolli PL
    Farmaco Sci; 1967 Aug; 22(8):627-40. PubMed ID: 6077137
    [No Abstract]   [Full Text] [Related]  

  • 25. The effects of some synthetic compounds on in vitro fibrinolytic activity measured by different methods and the relevance to activity in vivo.
    Baillie AJ; Sim AK
    Thromb Diath Haemorrh; 1972 Dec; 28(3):351-8. PubMed ID: 4265316
    [No Abstract]   [Full Text] [Related]  

  • 26. [The inhibitors of fibrinolysis].
    Badimón L; Villaverde CA; Bastida E; Badimón JJ; Valdecasas FG
    Arch Farmacol Toxicol; 1978 Apr; 4(1):98-9. PubMed ID: 697408
    [No Abstract]   [Full Text] [Related]  

  • 27. Medicinal chemical studies on antiplasmin drugs. 4. Chemical modification of trans-4-aminomethylcyclohexanecarboxylic acid and its effect on antiplasmin activity.
    Okano A; Inaoka M; Funabashi S; Iwamoto M; Isoda S
    J Med Chem; 1972 Mar; 15(3):247-55. PubMed ID: 5059209
    [No Abstract]   [Full Text] [Related]  

  • 28. [Antifibrinolytic agents, a new class of drugs].
    Markwardt F
    Internist (Berl); 1966 Aug; 7(8):400-5. PubMed ID: 4863412
    [No Abstract]   [Full Text] [Related]  

  • 29. The fibrinolytic system.
    Fearnley GR
    Proc R Soc Med; 1971 Sep; 64(9):923-5. PubMed ID: 5114291
    [No Abstract]   [Full Text] [Related]  

  • 30. [Heparin and fibrinolysis inhibitors].
    Villaverde CA; Badimón L; Vidal M; Badimón JJ; Valdecasas FG
    Arch Farmacol Toxicol; 1981 Apr; 7(1):97-100. PubMed ID: 7325724
    [No Abstract]   [Full Text] [Related]  

  • 31. Desmoteplase-mediated plasminogen activation and clot lysis are inhibited by the lysine analogue tranexamic acid.
    Niego B; Horvath A; Coughlin PB; Pugsley MK; Medcalf RL
    Blood Coagul Fibrinolysis; 2008 Jun; 19(4):322-4. PubMed ID: 18469556
    [No Abstract]   [Full Text] [Related]  

  • 32. Recent progress in fibrinolysis.
    Mannucci PM; Minetti D; Mari D
    Southeast Asian J Trop Med Public Health; 1979 Sep; 10(3):328-35. PubMed ID: 160079
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effect of sodium heparin on activated fibrinolysis in the rat in vivo].
    Badimón L; Villaverde C; Badimón JJ; Vidal M; Valdecasas FG
    Arch Farmacol Toxicol; 1981 Apr; 7(1):105-8. PubMed ID: 7325697
    [No Abstract]   [Full Text] [Related]  

  • 34. Complete inhibition of fibrinolysis by sustained carboxypeptidase B activity: the role and requirement of plasmin inhibitors.
    Walker JB; Bajzar L
    J Thromb Haemost; 2007 Jun; 5(6):1257-64. PubMed ID: 17389009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of heparin and AMCA on coagulation and fibrinolysis in blood and lymph following massive haemorrhage in dogs.
    Leandoer L; Bergentz SE; Nilsson IM
    Acta Chir Scand; 1969; 135(1):1-6. PubMed ID: 5805939
    [No Abstract]   [Full Text] [Related]  

  • 36. Therapeutics targeting the fibrinolytic system.
    Lin H; Xu L; Yu S; Hong W; Huang M; Xu P
    Exp Mol Med; 2020 Mar; 52(3):367-379. PubMed ID: 32152451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Studies on the use of p-aminomethyl benzoic acid ethyl ester as antifibrinolytic agent].
    Markwardt F; Klöcking HP; Vogel G
    Z Gesamte Inn Med; 1967 Oct; 22(19):569-74. PubMed ID: 5596621
    [No Abstract]   [Full Text] [Related]  

  • 38. [Pharmacological study of some inhibitors of fibrinolysis].
    Gavrilov AP
    Farmakol Toksikol; 1967; 30(4):460-3. PubMed ID: 5598902
    [No Abstract]   [Full Text] [Related]  

  • 39. [Determination of the components of fibrinolytic system].
    Slobozhankina IK
    Lab Delo; 1973; 11():662-4. PubMed ID: 4132568
    [No Abstract]   [Full Text] [Related]  

  • 40. [Antifibrinolytic therapy].
    Levi M; ten Cate JW
    Ned Tijdschr Geneeskd; 1995 Mar; 139(12):613-7. PubMed ID: 7700404
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.